Yüksek Riskli Diffüz Büyük B Hücreli Lenfoma Olgularında DA-EPOCH-R Deneyimi

Abstract

Anahtar Kelimeler: ABSTRACT Objective: We aimed to evaluate the impact of dose-adjusted EPOCH-R (DA-EPOCH-R) regimen on outcome parameters in high-risk, newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. Patients and Methods: Demographic and clinical features, response and survival parameters of patients presenting with DLBCL were retrospectively analyzed. Results: The study included a total of 33 patients (15 women, 18 men) with a median age of 49 (26-71). Seventeen, fourteen and eight patients had stage III/IV, high-intermediate/high risk IPI and double expressor lymphoma, respectively. Twenty six patients achieved complete remission. Two patients died as a result of sepsis. Estimated progression-free and overall survival were 79.7 ± 8.418 (63.21-96.2%; 95% CI) and 90.87 ± 6.74 (77.65-104.08%; 95% CI) months, respectively. Conclusion: DA-EPOCH-R is an effective but toxic regimen in DLBCL patients presenting with high-risk features.